Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$10.38 USD
+0.04 (0.34%)
Updated Jul 22, 2024 11:57 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALPMY 10.38 +0.04(0.34%)
Will ALPMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
New Strong Sell Stocks for October 2nd
New Strong Sell Stocks for September 26th
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for September18th
New Strong Sell Stocks for August 21st
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
Other News for ALPMY
Jefferies downgrades Astellas Pharma (ALPMF) to a Hold
Astellas Pharma, Osaka University enter research collaboration
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Astellas Pharma just downgraded at Jefferies, here's why
Astellas Announces Sponsored Research Agreement with UMass Chan Medical School